Marshall Wace, LLP Axsome Therapeutics, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$69.25 - $82.21 $9.16 Million - $10.9 Million	-132,263 Reduced 69.06%	59,248 $4.14 Million
Q2 2023 Aug 14, 2023	BUY	$58.41 - $90.35 $10.8 Million - $16.7 Million	184,390 Added 2589.38%	191,511 $13.8 Million
Q1 2023 May 15, 2023	BUY	$58.39 - $75.0 $415,795 - $534,075	7,121 New	7,121 $439,000
Q2 2022 Aug 15, 2022	BUY	$21.74 - $46.75 $595,523 - $1.28 Million	27,393 New	27,393 $1.05 Million
Q2 2021 Aug 13, 2021	SELL	$50.63 - $73.5 $1.18 Million - $1.72 Million	-23,374 Closed	0 $0

Q1 2021 May 17, 2021	BUY	$55.91 - $81.44 $1.31 Million - $1.9 Million	23,374 New	23,374 $1.32 Million
Q2 2020 Aug 13, 2020	SELL	$49.87 - $98.69 $3.96 Million - $7.84 Million	-79,454 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$41.2 - $101.31 $3.27 Million - $8.05 Million	79,454 New	79,454 $4.67 Million

290

37.1M

401K

464K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.38B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.